Blackmores Limited operates in the Medicinals and botanicals sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Blackmores Limited with three other
pharmaceutical manufacturers in Australasia:
Immuron Limited
(2020
sales of 2.52 million Australian Dollars [US$1.92 million]
of which 100%
was HyperImmune Products),
Palla Pharma Ltd
(22.10 million Australian Dollars [US$16.83 million]
of which 83%
was Norway), and
MGC Pharmaceuticals Ltd
(2.09 million Australian Dollars [US$1.59 million]
of which 100%
was Supply of medicinal cannabis products).
Sales Analysis.
Blackmores Limited reported sales of A$568.35 million (US$432.86 million)
for the
fiscal
year ending
June of 2020.
This
represents
a
decrease of 6.8%
versus 2019, when the company's sales were A$609.50 million.